UPDATE: Morgan Stanley Upgrades Haemonetics; Removes PT

According to a research report published this morning, Morgan Stanley has upgraded Haemonetics (NYSE: HAE) from Underweight to Equal-weight, and removed its $55 PT.

In the report, Morgan Stanley said, "We're upgrading Haemonetics to Equal-weight from Underweight. The Pall transaction may drive long term EPS upside and addresses our prior concerns on risk to estimates. Pipeline visibility is improving, but we'd need to see more to move to Overweight."

Haemonetics closed yesterday at $71.57.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.